086450 - Dong Kook Pharmaceutical Co., Ltd.

086450 Summary

Biopharma

Stock Price & Overview

₩21,600 -200 (-0.92%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩21,600 ≈ US$15 · Market cap ₩1.0tn (≈ $698m)

086450 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	926.9	812.2	731.0	661.6	594.2	559.1	482.3	400.8	354.8	309.7	259.9
Cost of Revenue	425.3	364.3	320.2	281.8	243.9	221.7	191.4	162.9	145.4	126.8	111.6
Gross Profit	501.6	447.9	410.8	379.8	350.3	337.4	290.8	237.9	209.4	182.9	148.4
Selling, General & Administrative	—	—	—	306.9	287.8	250.9	222.3	182.8	159.3	136.0	114.7
Operating Income	96.6	80.4	66.9	72.7	63.2	84.7	68.6	55.1	50.1	46.9	33.6
Finance Income	16.3	19.6	17.8	17.2	12.8	8.1	11.2	10.2	3.2	7.5	3.8
Finance Costs	18.6	14.6	21.8	22.1	6.0	9.0	5.3	1.6	3.5	1.7	2.2
Pretax Income	92.6	84.7	60.8	68.6	69.8	80.0	75.6	63.1	52.8	54.1	36.8
Income Tax Expense	18.7	22.4	12.0	13.9	16.8	22.2	16.6	13.7	11.9	13.4	9.6
Net Income	73.9	62.3	48.9	54.8	52.9	57.9	59.1	49.4	40.9	40.7	27.2
Total Comprehensive Income	70.5	59.5	49.1	57.3	53.9	57.5	57.4	47.6	40.1	40.4	25.9

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	1.06	0.95	0.84	0.77	0.75	0.66	0.54	0.48	0.37	0.33	0.27
Current Assets	0.57	0.47	0.42	0.39	0.42	0.40	0.34	0.30	0.27	0.23	0.20
Cash & Cash Equivalents	0.06	0.05	0.06	0.07	0.09	0.05	0.07	0.06	0.06	0.06	0.04
Inventories	0.18	0.16	0.14	0.12	0.10	0.08	0.06	0.06	0.05	0.05	0.03
Trade Receivables	0.22	0.18	0.16	0.13	0.12	0.12	0.10	0.10	0.10	0.09	0.09
Non-current Assets	0.50	0.48	0.42	0.38	0.33	0.26	0.21	0.18	0.10	0.09	0.08
Property, Plant & Equipment	0.31	0.30	0.27	0.26	0.23	0.19	0.16	0.14	0.07	0.06	0.06
Intangible Assets	0.04	0.04	0.02	0.01	0.01	0.01	0.00	0.00	0.00	0.01	0.01
Total Liabilities	0.30	0.27	0.26	0.24	0.27	0.23	0.16	0.15	0.09	0.09	0.07
Current Liabilities	0.27	0.23	0.23	0.20	0.24	0.16	0.11	0.09	0.08	0.07	0.06
Non-current Liabilities	0.03	0.04	0.03	0.04	0.03	0.06	0.05	0.06	0.01	0.01	0.02
Total Equity	0.76	0.68	0.58	0.53	0.48	0.44	0.39	0.33	0.28	0.24	0.20
Share Capital	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.04	0.04
Retained Earnings	0.61	0.56	0.51	0.47	0.42	0.38	0.33	0.28	0.24	0.20	0.17

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	68.8	76.1	41.8	40.9	44.7	59.1	69.5	33.2	28.7	39.4	27.1
Cash from Investing Activities	-61.6	-64.9	-52.4	-12.4	-43.5	-96.9	-55.8	-90.7	-17.4	-15.6	-17.3
Purchase of Property, Plant & Equipment	42.7	26.6	33.9	47.2	51.0	39.6	25.1	75.5	11.7	9.5	9.1
Cash from Financing Activities	-1.0	-22.3	-2.3	-39.8	29.7	23.0	-4.9	56.1	-3.3	-4.5	0.7
Dividends Paid	9.2	8.3	8.1	8.0	8.0	7.2	4.7	4.6	3.5	2.6	2.6
Net Change in Cash	6.1	-11.1	-12.9	-11.3	30.9	-14.9	8.7	-1.4	7.9	19.3	10.6

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	258.9	251.0	242.9	226.8	233.5	223.7	210.9	200.9	203.5	196.8
Cost of Revenue	114.9	110.2	110.0	102.4	109.1	103.8	97.2	89.4	90.8	86.9
Gross Profit	144.0	140.8	132.9	124.4	124.4	119.9	113.8	111.4	112.8	109.9
Selling, General & Administrative	—	—	—	—	—	—	—	89.9	93.1	88.9
Operating Income	26.1	27.3	24.3	24.8	22.1	25.3	17.7	22.5	19.2	21.0
Finance Income	2.8	7.3	4.8	4.6	2.6	4.3	6.4	4.0	3.2	6.0
Finance Costs	5.0	3.8	6.8	0.5	8.1	3.2	5.4	0.9	5.0	3.2
Pretax Income	23.3	30.2	17.8	28.8	23.3	22.7	15.5	26.6	17.5	25.1
Income Tax Expense	6.1	3.9	2.2	6.5	5.2	4.7	7.2	5.4	4.7	5.1
Net Income	17.2	26.3	15.6	22.3	18.1	18.0	8.3	21.2	12.8	20.0
Total Comprehensive Income	17.0	25.9	14.4	21.6	18.2	16.3	5.8	21.0	12.8	19.9

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	1.12	1.09	1.06	1.04	1.00	0.98	0.95	0.92	0.90	0.87
Current Assets	0.59	0.57	0.57	0.55	0.54	0.51	0.47	0.48	0.46	0.44
Cash & Cash Equivalents	0.07	0.06	0.06	0.05	0.07	0.07	0.05	0.03	0.03	0.05
Inventories	0.19	0.18	0.18	0.18	0.17	0.16	0.16	0.17	0.16	0.15
Trade Receivables	0.24	0.23	0.22	0.21	0.21	0.19	0.18	0.19	0.19	0.17
Non-current Assets	0.53	0.52	0.50	0.49	0.46	0.47	0.48	0.44	0.44	0.43
Property, Plant & Equipment	0.34	0.33	0.31	0.31	0.29	0.30	0.30	0.28	0.28	0.27
Intangible Assets	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.02	0.02	0.02
Total Liabilities	0.32	0.31	0.30	0.29	0.28	0.28	0.27	0.26	0.26	0.28
Current Liabilities	0.29	0.28	0.27	0.26	0.24	0.24	0.23	0.23	0.23	0.25
Non-current Liabilities	0.03	0.03	0.03	0.03	0.04	0.04	0.04	0.04	0.03	0.03
Total Equity	0.80	0.78	0.76	0.74	0.72	0.70	0.68	0.66	0.64	0.59
Share Capital	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Retained Earnings	0.65	0.63	0.61	0.60	0.58	0.57	0.56	0.55	0.53	0.52

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	32.3	22.6	23.5	11.4	23.0	10.8	30.6	14.4	15.9	15.2
Cash from Investing Activities	-3.9	-8.9	-16.9	-39.5	4.5	-9.7	-12.2	-11.5	-28.5	-12.8
Purchase of Property, Plant & Equipment	19.1	13.1	13.8	10.3	14.0	4.6	5.3	6.7	7.7	6.9
Cash from Financing Activities	-12.5	-12.1	0.2	10.0	-26.0	14.9	-2.2	-1.0	-8.8	-10.3
Dividends Paid	—	—	0.0	0.0	—	—	0.0	0.0	—	—
Net Change in Cash	15.8	1.6	6.8	-18.1	1.5	16.0	16.1	1.9	-21.3	-7.9

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

086450 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	926.9	+14.1%	+11.9%	+10.6%	+13.6%
Operating income	96.6	+20.1%	+9.9%	+2.6%	+11.1%
Net income	73.9	+18.6%	+10.5%	+5.0%	+10.5%
EPS	₩1,635	+18.6%	+10.5%	+5.0%	+10.5%
Operating cash flow	68.8	-9.6%	+18.9%	+3.1%	+9.7%
Shareholders' equity	763.7	+12.5%	+12.9%	+11.9%	+14.3%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

086450 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	54.1%	55.1%	56.2%	57.4%	58.9%	60.3%
Operating margin	10.4%	9.9%	9.1%	11.0%	10.6%	15.2%
Net margin	8.0%	7.7%	6.7%	8.3%	8.9%	10.4%
Return on equity	10.2%	9.9%	8.8%	10.8%	11.5%	14.1%
Return on assets	7.3%	7.0%	6.1%	7.2%	7.5%	9.6%
Operating cash flow / revenue	7.4%	9.4%	5.7%	6.2%	7.5%	10.6%
Capex / revenue	4.6%	3.3%	4.6%	7.1%	8.6%	7.1%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 086450

Symbol	Last Price
127120JS Link	₩33,600 +12.4%
475830Orum Therapeutics, Inc.	₩55,900 +2.6%
195940HK inno.N Corporation	₩42,050 +0.7%
003090Daewoong Co., Ltd.	₩16,860 -2.0%
185750Chong Kun Dang Pharmaceutical Corp.	₩68,000 -0.3%
115180Qurient Co., Ltd.	₩23,050 +17.3%
476830Rznomics, Inc.	₩28,200 +6.8%
003850Boryung Corporation	₩9,040 +1.6%
950260Ingenia Therapeutics Inc.(reg.s)	₩15,580 -1.5%
085660Chabiotech Co., Ltd.	₩8,090 +2.1%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.